Column writers of the Media/New Ports Unit (Small public xlgg-sina)

Perhaps the Port Unit is in the “B” series or is now experiencing a “crisis resolution” in the city of bears. In the Hong Kong Stock Market, three shares with B have been created, respectively, in Sindh Bio-B(01801), in the Anthem Pharmaceutical-B(01672), in the State of Myis-B (06160).

“When a powerful large company is confronted with a huge but soluble crisis, an extreme investment opportunity is tired.” This is the original word of Bafit.

Perhaps the Port Unit is in the “B” series or is now experiencing a “crisis resolution” in the city of bears. In the Hong Kong Stock Market, three shares with B have been created, respectively, in Sindh Bio-B(01801), in the Anthem Pharmaceutical-B(01672), in the State of Myis-B (06160).

This is a special arrangement for port transport, which, in order to alert investors to the risks of “equal rights” and of “unprofitable biotechnologies and market companies”, is covered by the code of title of the port’s shareholdings, requiring listed companies to add special markings W’ and B’ after their shares.

It is worth noting that the State is also the first domestic geotechnical company in the United States and Hong Kong, both on a dual market. Under the naming rules of the port of entry, the second market is subject to the addition of a special marker `S’ at the end of the stock abbreviations.

In the case of Perish-B(06160) whose second market (S) is marked, it will be lost to the deep-seated qualifications, and inland investors will not be able to purchase the equities and will be financially profitable. It also seems inappropriate to add this name to [SB].

According to the exchangeer, the State of Donigi is in Hong Kong a dual major market (Dual Primary Listing) rather than a secondary listing (secondary listing). The dual main market entry implies that companies need to comply simultaneously with market rules on both sides, which also pave the way for their future access to deep ports.

The first unit with “B” was marketed on 1 August. China believes that the aesthetic pharmaceuticals are the first in Hong Kong’s unprofitable new unit of biotechnological enterprises, and that domestic pharmacies dominate the Chinese market, with great potential for future profit. The pharmacological pharmaceutical is a national pilot of liver C, with the first liver therapy developed by Chinese domestic enterprises in the commercial phase. Currently, there are 25 million liver patients in China, but there is no effective vaccine and the healing rate is very low. Thus, the two liver-innovated drugs developed by the axopharmaceutical pharmaceuticals can be called the coal for domestic patients.

The public sale of the first singer in the market was 9.13 times higher, and in the absence of performance, investors were generally very cautious, resulting in a drop in the port unit’s entry into the market and a drop in the price of the artefacts, which eventually led to the sale of the 14 yuan renminbi, until the value of the unit went to $5.58, which was still worse than the price.

However, in September 2018, when the Trinity Pharmaceuticals were published, a sudden announcement of profits was made and the port equity investor began to re-examine the business with “B”.

The study of financial securities shows that the company’s performance is expected to be threefold: a platform for integration of anti-virus drugs, with promising prospects; a domestic market for hepatitis C drugs, which is at an early stage of rapid expansion, has begun to contribute to performance; and a long-term development of new drugs, such as anti-AIDS, liver fat, etc.

When the Business Proclamation Gonower (Donowe) has entered a pilot project for hepatitis C medical outpatient care in the city of Tianjin on a human-head fee basis, the equity price of the anthey pharmaceuticals ensues by more than 40 per cent. However, it was considered by APP that its competitors, “Ty Three Generations”, were declared included in the 2018 version of the national pharmacological catalogue. At the policy level, once three generations have advanced the national medical insurance catalogue, there is nothing to do with the products of the singer pharmaceuticals.

However, it can be shown that the increase in the unit’s share is clearly influenced by a positive shift in performance, and in this sense, the port unit has a “B” vote, which is meant by a “wind (risk investment) scientific progress”. Non-professional candidates are blind to follow-up in the face of inadequate information, and it is difficult to say that benefits are stable. Of course, risks and profits are positive.

The State of the Wisnum-B was then named in Hong Kong. The business, which focused on the development of anticological drugs, in particular anticological treatment for cancer, and on immunization of tumours, was established in Beijing in 2010 and was marketed in Nassau, United States, in February 2016, at a time when the market price was $24, the equity price was about six times higher than it had been for two years, and the market value was $70 billion, indicating whether the American equity investor had a considerable interest in its future potential.

As a global pioneer of cancer-innovative therapy, companies include a variety of potential best clinical stages of cancer resistance in product lines. The equity prices of such companies are in fact related to the timing of the product line. According to APP, the State of Survivors is expected to submit its first new application in China for the treatment of repeat/disciplinary cellular gonorm. The production plant in the State of Sur, Wizithe, is now ready for immediate production once a market permit is granted.

Overseas, zanubrutinib was granted a fast link in July 2018 by the FDA for the treatment of balloon-based hypergenocidal, and the company is expected to submit to the FDA, in the first half of 2019, a new medicinal application for balloon-based seros.

Before Hong Kong’s plate, the State of the Widziy publicly sells 1.73 times more than purchase, with a 100 per cent mark-up rate, with a final pricing of S$108. This price is marketed, and it does discourage many port equity investors.

Hundreds of goats are currently in the market phase of the port’s stock of fires in the city of bears, especially the medicinal brands. The lowest post-listed equity value was found to be $6.05, while the Hong Kong market was still low in terms of the recognition of such a loss enterprise, and if there was no foreign-owned bunker, it was necessary for the general business to see the performance before the investor dared to go to the bunker.

The founder, Wang Xiaodong, of the State of Myie, stressed in Hong Kong that, despite uncertainty over time, companies were constantly developing new anti-cancerous medicines in a scientific manner, believing that more new medicines would be available in the future and that they could be lost for one day. This is to say to port equity investors who do not see rabbits as a whole.